October 26-28, 2026 | Amsterdam
World Orphan Drug Congress Europe 2026
WODC Europe focuses on the development of therapies for rare and orphan diseases, including accelerated regulatory pathways and small patient populations.
Peregrion attends to discuss AMS microtracer studies in the context of orphan drug development, where early ADME insights are particularly relevant.
Activities
1:1 sponsor meetings throughout the conference.
Attending from Peregrion
- Suzanne van Gerwen (VP Business Development)
Topics for discussion
- Compressed ADME timelines for orphan drug programs
- More efficient design of later-stage clinical studies
- Mass balance and metabolite work with reduced radioactive burden
- Integration of AMS data into regulatory submissions for accelerated pathways
- Program-specific discussions
Book a meeting with our team: info@peregrion.com.
